DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is limited evidence that imaging biomarkers can predict subsequent response to therapy. Such prognostic and/or predictive biomarkers would facilitate development of personalised medicine. We hypothesised that pre-treatment measurement of the heterogeneity of tumour vascular enhancement could predict clinical outcome following combination anti-angiogenic and cytotoxic chemotherapy in colorectal cancer (CRC) liver metastases. METHODS: Ten patients with 26 CRC liver metastases had two dynamic contrast-enhanced MRI (DCE-MRI) examinations before starting first-line bevacizumab and FOLFOX-6. Pre-treatment biomarkers of tumour microvasculature were computed and a regression analysis was performed against the post-treatment change in tumour volume after five cycles of therapy. The ability of the resulting linear model to predict tumour shrinkage was evaluated using leave-one-out validation. Robustness to inter-visit variation was investigated using data from a second baseline scan. RESULTS: In all, 86% of the variance in post-treatment tumour shrinkage was explained by the median extravascular extracellular volume (v(e)), tumour enhancing fraction (E(F)), and microvascular uniformity (assessed with the fractal measure box dimension, d(0)) (R(2)=0.86, P<0.00005). Other variables, including baseline volume were not statistically significant. Median prediction error was 12%. Equivalent results were obtained from the second scan. CONCLUSION: Traditional image analyses may over-simplify tumour biology. Measuring microvascular heterogeneity may yield important prognostic and/or predictive biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621 · cited 1×
“The presence and degree of heterogeneity may be an important determinant of cancer metastatic potential (Fidler, 1987) and response to therapy (Casanovas et al, 2005).”
BackgroundQuantifying spatial heterogeneity in dynamic contrast‐enhanced MRI parameter maps
Rose, C. J., Mills, S. J., O'Connor, J. P. B., Buonaccorsi, G. A., Roberts, C., Watson, Y., Cheung, S., Zhao, S., Whitcher, B., Jackson, A., et al. (2009) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22003 · Cited by 125 · cited 2×
“These latter metrics retain magnitude values of Ktrans, ve, and vp and are described in detail elsewhere (Rose et al, 2009).”
BackgroundMethodSelf-citation
Cited by
Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?
Davnall, F., Yip, C. S. P., Ljungqvist, G., Selmi, M., Ng, F., Sanghera, B., Ganeshan, B., Miles, K. A., Cook, G. J., & Goh, V. (2012) · Insights into Imaging · doi:10.1007/s13244-012-0196-6 · Cited by 878
Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
O'Connor, J. P. B., Rose, C. J., Waterton, J. C., Carano, R. A. D., Parker, G. J. M., & Jackson, A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0990 · Cited by 677
Self-citationThe Biological Meaning of Radiomic Features
Tomaszewski, M. R., & Gillies, R. J. (2021) · Radiology · doi:10.1148/radiol.2021202553 · Cited by 549
Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis
Chicklore, S., Goh, V., Siddique, M., Roy, A., Marsden, P. K., & Cook, G. J. R. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2247-0 · Cited by 488
Characterization of PET/CT images using texture analysis: the past, the present… any future?
Hatt, M., Tixier, F., Pierce, L., Kinahan, P. E., Le Rest, C. C., & Visvikis, D. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3427-0 · Cited by 475
Radiomics: a new application from established techniques
Parekh, V., & Jacobs, M. A. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1164013 · Cited by 369
Sala, E., Mema, E., Himoto, Y., Veeraraghavan, H., Brenton, J. D., Snyder, A., Weigelt, B., & Vargas, H. A. (2017) · Clinical Radiology · doi:10.1016/j.crad.2016.09.013 · Cited by 369
The Biological Meaning of Radiomic Features
Tomaszewski, M. R., & Gillies, R. J. (2021) · Radiology · doi:10.1148/radiol.2021219005 · Cited by 327
Perfusion and vascular permeability: Basic concepts and measurement in DCE-CT and DCE-MRI
Cuenod, C. A., & Balvay, D. (2013) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2013.10.010 · Cited by 312
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Metadata
- Authors
- O'Connor, J. P. B., Rose, C. J., Jackson, A., Watson, Y., Cheung, S., Maders, F., Whitcher, B. J., Roberts, C., Buonaccorsi, G. A., Thompson, G., Clamp, A. R., Jayson, G. C., & Parker, G. J. M.
- Venue
- British Journal of Cancer
- Published
- 2011-06
- Volume
- 105
- Issue
- 1
- Pages
- 139-145
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2125328123
- Cited by
- 136
- References
- 2
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.